Skip to main content

Table 2 Patients receiving scheduled treatment per cycle

From: Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial

 

Capecitabine

Fluorouracil

Adjuvant Cohort1

 1

107 (98%)

109 (100%)

 2

105 (96%)

106 (97%)

 3

102 (94%)

101 (93%)

 4

99 (91%)

96 (88%)

 5

98 (90%)

92 (84%)

 6

90 (83%)

–

Neoadjuvant Cohort2

 1

66 (93%)

71 (99%)

 2

50 (70%)

46 (64%)

 3

46 (65%)

38 (53%)

 4

42 (59%)

35 (49%)

 5

40 (56%)

32 (44%)

 6

37 (52%)

–

  1. Data are n (%)
  2. 1n = 109 Capecitabine, n = 109 Fluorouracil;
  3. 2n = 71 Capecitabine, n = 72 Fluorouracil
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us